ArticleNPJ vaccines2024
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation.
Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Development of a unified mass cytometry assay integrating activation-induced markers (AIMs) and cytokine profiling for high-throughput assessment of antigen-specific T cell responses.Human vaccines & immunotherapeutics · 2026Article
- Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows.Cell reports methods · 2026Article
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- A novel CD69 binding ankyrin repeat protein (AnkyronResearch square · 2026Article
- Cancer and COVID-19: A review of immune insights and partnerships to inform public health strategy.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026Review
- Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.Molecular biology reports · 2026Review
- Endemic penetrance of SARS-CoV-2 has impacted marginally on immunity to spike protein of human coronaviruses.Communications biology · 2026Article
- Humoral and cell mediated immune response to SARS-CoV-2 vaccination in patients with immune-mediated diseases.Frontiers in immunology · 2026Observational
- Combining Activation-Induced Markers With PD-L1 Selectively Enhances Detection of Antigen-Specific T Cells in Virus-Infected Individuals.Journal of immunology research · 2026Article
- T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome - a prospective cohort study.Human vaccines & immunotherapeutics · 2025Observational
- UnveilingiScience · 2025Article
- Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines.NPJ vaccines · 2025Review
- Ethnic Comparisons of Spike-Specific CD4+ T Cells, Serological Responses, and Neutralizing Antibody Titers Against SARS-CoV-2 Variants.Vaccines · 2025Article
- Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA-Protein Networks.International journal of molecular sciences · 2025Article
- Exploring diverse approaches for predicting interferon-gamma release: utilizing MHC class II and peptide sequences.Briefings in bioinformatics · 2025Article
- T-Cell Interferon Gamma Responses to SARS-CoV-2 Following Infection with/Without Vaccination in a Tanzanian Population.Infection and drug resistance · 2025Article
- Validation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2.Human vaccines & immunotherapeutics · 2024Article
- Comparison of different T cell assays for the retrospective determination of SARS-CoV-2 infection.The Journal of general virology · 2024Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Measuring SARS-CoV-2-specific T cell responses is crucial to understanding an individual's immunity to COVID-19. However, high inter- and intra-assay variability make it difficult to define T cells as a correlate of protection against COVID-19. To address this, we performed systematic review and meta-analysis of 495 datasets from 94 original articles evaluating SARS-CoV-2-specific T cell responses using three assays - Activation Induced Marker (AIM), Intracellular Cytokine Staining (ICS), and Enzyme-Linked Immunospot (ELISPOT), and defined each assay's quantitative range. We validated these ranges using samples from 193 SARS-CoV-2-exposed individuals. Although IFNγ ELISPOT was the preferred assay, our experimental validation suggested that it under-represented the SARS-CoV-2-specific T cell repertoire. Our data indicate that a combination of AIM and ICS or FluoroSpot assay would better represent the frequency, polyfunctionality, and compartmentalization of the antigen-specific T cell responses. Taken together, our results contribute to defining the ranges of antigen-specific T cell assays and propose a choice of assay that can be employed to better understand the cellular immune response against viral diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.